An Open-label, Uncontrolled, Phase II Trial Evaluating the Single-dose and Steady-state Pharmacokinetics of EndoTAG®-1 and Its Effect on the Blood Supply and the Angiogenesis of Hepatic Metastases in Patients With a Carcinomatous Primary Tumor Other Than Hepatocellular (HCC), Biliary or Bile Duct Carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- MediGene
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Pharmacokinetic profile
研究概览
简要总结
The primary objective of study CT 4003 is to assess the behavior of EndoTAG®-1 in the body (making a so-called pharmacokinetic profile). Therefore, the course of the drug in the body is examined, i.e. the amount and speed of the drug uptake as well as the distribution and the elimination of the drug is being investigated. Further objectives of the study are to assess the effect of EndoTAG®-1 on liver metastases concerning size and blood supply measured by imaging techniques (contrast-enhanced ultrasound and magnetic resonance imaging as well as duplex sonography) and to assess the effect on blood markers which are indicators for the destruction and neoplasm of blood vessels (so-called markers of angiogenesis).
详细描述
Liver metastases are among the most frequent neoplasms of the liver and represent a quite uniform clinical entity regardless from which carcinoma they originate. The treatment is dependent on number and size of the hepatic lesions but still, none of the therapeutic options leads to satisfying results. The growth of tumors and metastases is dependent on blood vessels, which supply the tumors and metastases with nutrients. Liver metastases, independent from which original tumor they come from, are especially well supplied with blood. The aim of the treatment with the investigational medicinal product EndoTAG®-1 is to target the blood vessels, which supply the metastases, and destroy them. Consequently, the metastases themselves will be damaged.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable hepatic metastases of a carcinomatous origin with exception of HCC, biliary or bile duct carcinoma
- •At least one measurable hepatic metastases > 20 mm in diameter (measured in MRI)
- •Last application of palliative chemotherapy (drug dependent on the primary tumor) at least 7 days ago
- •Gender: male and female (at least 6 individuals of each gender)
- •Age >= 18 years
- •Negative pregnancy test (females of childbearing potential)
- •Willingness to perform double-barrier-contraception during the study and for 6 month post study medication
- •ECOG performance status 0,1 or 2
- •Assumed life expectancy of > 3 month
- •Signed informed consent
排除标准
- •History of significant liver pathology (other than metastases, e.g. cirrhosis of the liver, PSC, PBC) or liver transplantation
- •Laboratory tests (hematology, chemistry) outside specific limits:
- •ANC <= 1.0 x 10^9/L
- •Platelets <= 100 x 10^9/L
- •Hb <= 9.0 g/dL (<= 5.6 mmol/L)
- •Total Bilirubin > 2.0 mg/dL
- •Serum Creatinine > 1.5 mg/dL
- •Renal insufficiency with a GFR < 60 mL/min
- •Currently ongoing taxane-containing palliative chemotherapy regimen or history of taxane administration within 4 weeks prior to study entry
- •Pregnancy or nursing status
- •Positive HIV, HBV or HCV testing
- •The patient has a contraindication for MRI or CEUS according to accepted clinical guidelines
- •Known hypersensitivity to any component of the EndoTAG®-1 formulation, gadolinium-based MR-contrast media or sulphur hexafluoride
- •Claustrophobia or history of active or significant neurological disorder and/or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere in the clinical and radiological evaluation of the patient during the trial
- •Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry
研究组 & 干预措施
1
干预措施: EndoTAG®-1 (Drug)
结局指标
主要结局
Pharmacokinetic profile
时间窗: Last patient out
次要结局
- Tumor response, Tumor perfusion, Soluble markers of angiogenesis, Pharmacodynamics, Safety(Last patient out)